Abstract:
A novel and unique plasminogen activator inhibitor fragment is obtained from human umbilical vein endothelial cells which has the following characteristics:A. it is derived from a native t-PA inhibitor that binds to and inhibits the activity of t-PA,B. it is dissociated from a complex formed between said native t-PA inhibitor and t-PA, said complex existing in two distinct interconvertible conformations with molecular weight of about 88 KDa and 105 KDa, respectively, and being partially reversible in the presence of fibrin,C. it has a molecular weight of about 40 KDa when dissociated from the complex, andD. it has a novel partial N-terminal amino acid sequence when dissociated from the complex.
Abstract:
Plasminogen activators (PA) are obtained from cultured normal human colon cells which are adaptable to large scale production. A purified tissue PA (t-PA) is obtained from CCD-18Co normal human colon fibroblast cells which shows chemical differences from Bowes melanoma t-PA.
Abstract:
A method of producing antibodies against vascular permeability factor (VPF) is disclosed which comprises immunizing a host animal with a peptide having an amino acid sequence as follows: ##STR1## or a fragment of said peptide containing an antigenic determinant of VPF.
Abstract:
Glycosylated plasminogen activator (t-PA) having a glycosylation pattern significantly different than exhibited by t-PA from Bowes melanoma cells is obtained from cultured normal human colon fibroblast cells (CCD-18Co).
Abstract:
A monoclonal antibody is disclosed which is specific for human colon fibroblast-derived tissue plasminogen activator (t-PA), and which is useful for immunoaffinity chromatography purification of t-PA and determination of t-PA in a biological sample.
Abstract:
Process for the production of human angiogenic factor in vitro comprising growing the human diploid cell line IMR-90 on support surface in nutrient culture medium at about 35.degree.-38.degree. C. for a sufficient time to elaborate angiogenic factor and recovering the resulting angiogenic factor from the cells or cell product.
Abstract:
Process for the production of human TAF in vitro comprising growing the human melanoma cell line A-375 in agitated, liquid suspension of nutrient culture medium at about 35.degree.-38.degree. C. for a sufficient time to elaborate TAF and recovering the resulting TAF from the cells or cell product.
Abstract:
A cell culture sampling device is provided which comprises a double septum holder having an axial bore therethrough, upper and lower septa retaining members, said upper retaining member having lip means to retain immobilized an external septum and said lower retaining member having shoulder means to retain immobilized an internal septum, said lip and shoulder means being spaced apart to thereby define a fixed chamber between said immobilized septa.
Abstract:
A cell culture system and apparatus is provided for the suspension culturing of mammalian cells in which fresh media can be added and spent medium filtered and withdrawn on a continuous or semi-continuous basis without cell disruption. The apparatus comprises a hollow flask assembly having a hollow shaft means journaled for rotation in a stationary sleeve sub-assembly and a filter unit suspended downwardly therefrom, said filter unit being in fluid communication with the top opening of the flask through the interior of said hollow shaft means and adapted for coaxial rotation with said shaft means.
Abstract:
A cell culture reactor system is provided for the growth of cells in vitro which employs elongate hollow or solid fibers arranged in a shallow layer configuration as a matrix for cell attachment in which the flow path of the culture media is directed substantially uniformly through the fiber layer and substantially transverse to the plane of the elongate axes of the fibers.